All News

Lumbar rash DM

MAXIMISE Trial - Secukinumab Efficacy in Psoriatic Spondylitis Patients

Jack Cush, MD
Feb 26, 2021

The results of the novel MAXIMISE trial have been published, demonstrating that secukinumab significantly improved axial signs and symptoms in psoriatic arthritis patients with axial manifestations with inadequate NSAID response.

Read Article
RheumNow Podcast square

RheumNow Podcast – Sweet Lies or Hard Truths? (2.26.2021)

Jack Cush, MD
Feb 26, 2021

Dr. Jack Cush reviews and discusses the news and Journal reports from the past week on RheumNow.com.

Read Article
We are three weeks out from RheumNow Live. Are you planning on attending? https://t.co/vJlU0Z3Q3x

Links:

Dr. John Cush RheumNow ( View Tweet)

Feb 26, 2021
Data from Danish Medical Birth Register shows PREG women w/ spondyloarthritis have more adverse pregnancy outcomes - including preterm birth (OR 1.5), elective C-section (OR 1.44), & epidurals (OR 1.11). Not increased were preeclampsia & rate small wt. https://t.co/opYsOBAR6A

Links:

Dr. John Cush RheumNow ( View Tweet)

Feb 22, 2021
Survery of 438 RHEUMS on #AS & SpA - half use mod NY & ASAS criteria. 3/4 say Inflammatory Back Pain is axSpA specific, ~1/2 say uveitis/dactylitis are “very specific; less so heel enthesitis, peripheral arthritis. SI MRI was mor common w/ younger Rheums https://t.co/xfjvK5TO0t

Links:

Dr. John Cush RheumNow ( View Tweet)

Feb 22, 2021
RWCS Highlights - Day 2 by Dr. Rachel Tate ( @uptotate) -What’s new in Spondyloarthritis -Osteoporosis and Beyond -Immunologic basis and clinical characteristics https://t.co/q4lI2BYhfz https://t.co/Q79CHaQrHf

Links:

Dr. John Cush RheumNow ( View Tweet)
Feb 15, 2021
Upadacitinib works very well in ankylosing spondylitis. Will JAKs soon be approved in #AS @RWCSmtg @JointMD https://t.co/09KFo3mYJs
Dr. John Cush RheumNow ( View Tweet)
Feb 11, 2021
Tofacitinib shown to work very well in ankylosing spondylitis. @RWCSmtg @JointMD https://t.co/r1yIL96HyQ
Dr. John Cush RheumNow ( View Tweet)
Feb 11, 2021
But.... Etanercept was not effective in a small study of "pre-axSpA"(not having MRI SI or Elevated CRP. Low level responses in this study @RWCSmtg @JointMD https://t.co/ofIbByefMH
Dr. John Cush RheumNow ( View Tweet)
Feb 11, 2021
Eranercept works in nonrad AxSpA @RWCSmtg @JointMD https://t.co/PFTqNj6R3s
Dr. John Cush RheumNow ( View Tweet)
Feb 11, 2021
TICOSPA,. Right control in axSpA didn't work so well, even though the TV group water twice as likely to get advanced therapies @RWCSmtg @JointMD https://t.co/Jm9vHAPwCN
Dr. John Cush RheumNow ( View Tweet)
Feb 11, 2021
Dr Eric Ruderman shows x-ray progression is different/lower in non radiographic AxSpA @RWCSmtg https://t.co/tqI3xKhDuJ
Dr. John Cush RheumNow ( View Tweet)
Feb 11, 2021
Dr Eric Ruderman shows when pts are referred by MDs, vs self referred, they are more likely to have AxSpA (40 percent). Lectures from RWCS @RWCSmtg https://t.co/mRtMictVpq
Dr. John Cush RheumNow ( View Tweet)
Feb 11, 2021
Covid vaccine

ACR Promotes New COVID-19 Vaccine Clinical Guidance for Rheumatic Patients

Jack Cush, MD
Feb 10, 2021

The American College of Rheumatology has published a draft guidance on the use of COVID-19 vaccination in rheumatic disease and musculoskeletal disease patients, based on the efforts of the North American Task force. The document provides guidance to rheumatology providers on the use of the COVID-19 vaccine and the associated management of RMD patients around the time of vaccination. Here is a summary of the recommendations.

Read Article
CV cardiac heart

Comorbidity and Drugs Drive COVID-19 Severity and Survival in Rheumatic Disease

Jack Cush, MD
Feb 09, 2021

While comorbidities are associated with severe COVID-19 infection, it appears they also influence severity and survival in rheumatic disease (RMD), according to a a French cohort study,

Read Article
RheumNow Podcast square

RheumNow Podcast – Tofacitinib Safety Concerns (2.5.2021)

Jack Cush, MD
Feb 05, 2021

Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.

Read Article
Download available--Maintaining a Healthy Immune System https://t.co/wiWzZldnik https://t.co/ZL3r3dHPC2

Links:

Dr. John Cush RheumNow ( View Tweet)
Feb 01, 2021
British registry 801 axial SpA pts; 646 did not hve fibromyalgia at baseline & 46 (7%) developed FM over time. Of 115 axSpa w/ baseline FM, 77 (2/3) recovered. FM more likely with high Dz activity ((OR 1.27) & widespread pain (OR 1.14) https://t.co/4jOdaXIJuB https://t.co/ruOYj5HmMX

Links:

Dr. John Cush RheumNow ( View Tweet)
Feb 01, 2021
Sign up for RheumNow Live, March 20 and 21st. CME credits available. https://t.co/uwxOVh142F https://t.co/GqkCLBGl62

Links:

Dr. John Cush RheumNow ( View Tweet)
Jan 31, 2021
patient.safety_1.jpg

JAK Inhibitor Misses Endpoint in Safety Study. Now What?

MedPage Today
Jan 27, 2021

Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class.

Read Article

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2021 All Rights Reserved.

×